<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) both a <z:e sem="disease" ids="C0019087" disease_type="Disease or Syndrome" abbrv="">haemorrhagic diathesis</z:e> and a tendency to <z:mp ids='MP_0005048'>thrombosis</z:mp> of the venous and arterial vessels can be observed </plain></SENT>
<SENT sid="1" pm="."><plain>In the course of the disease, <z:mp ids='MP_0005048'>thrombosis</z:mp> of the leg or pelvic veins developed in 20 per cent of 188 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The levels of alpha 2-plasmin inhibitor, plasminogen, fibronectin and of factor VIII complex were increased in patients with SLE compared with a control group </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty per cent of the patients showed no increase in fibrinolytic activity after venous occlusion measured with the fibrin plate method </plain></SENT>
<SENT sid="4" pm="."><plain>This suggests a reduced fibrinolytic capacity in SLE probably caused by alteration of the endothelial cells through immune complex <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and an acquired <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> in <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> in SLE are to be considered thrombophilic mechanisms </plain></SENT>
<SENT sid="6" pm="."><plain>In the individual case there is an overlapping of hyper- and hypocoagulability </plain></SENT>
</text></document>